Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

SGLT2 Inhibition in Addition to Lifestyle Intervention and Risk for Complications in Subtypes of Patients With Prediabetes - a Randomized, Placebo Controlled, Multi-center Trial

NCT06054035 is registered in ClinicalTrials.gov with University Hospital Tuebingen as lead sponsor.

NCT NCT06054035
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06054035 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
SGLT2 Inhibition in Addition to Lifestyle Intervention and Risk for Complications in Subtypes of Patients With Prediabetes - a Randomized, Placebo Controlled, Multi-center Trial
Lead sponsor
University Hospital Tuebingen
Phase
Phase 4
Overall status
Recruiting
Start date
October 26, 2023
Completion date
September 30, 2027
Enrollment
170 (estimated)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

prediabetes, renal failure, type2diabetes